Advertisement Pharmaceutical Business review - Page 170 of 5217 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 31, 2024

Pinetree secures $17m to advance TPD development programmes

Pinetree Therapeutics has secured $17m in a Series A funding round to advance its new multispecific targeted protein degraders (TPD) development programmes.

The advancement is expected to propel TPD development programmes targeting multiple tumour types and oncology indications. Credit: Tung Lam from Pixabay.